




EMORY  
UNIVERSITY

Office of Technology Transfer


# Annual Report 2017




## AUTM Reportable Agreements




## Proof of Principle Funding




## Patent Applications & Issued




## Industry Funding



## Industry Contracts



## Network of Outgoing Corporate Agreements Fiscal Year 2017





**EMORY**  
UNIVERSITY

## Office of Technology Transfer



**Todd Sherer, PhD**  
*Assoc. VP for Research,  
Executive Director*

# A Record Year

This past year brought many new milestones for Emory University. To begin with, Emory received a record high of \$628M in sponsored research funding, with an all-time high of \$63.63M coming from industry to support clinical trials and research, but that is just the beginning. Research funding continues to drive activity in the office and our inventors disclosed a record number of 245 new inventions to the office. As deal makers, we completed a grand total of 2,216 agreements between industry contracting and technology transfer, another record. Most of these are with our industry partners and lead to sponsored research funding and licensing new inventions.

Emory startups had an excellent year on a number of fronts. Emory received a record high of \$1,796,772 in translational funding to support future spin-out technologies while launching a record 8 new startups. Existing Emory startups raised \$116M from venture capitalists

and high-net-worth individuals, with \$95M of that raised by Carrick Therapeutics based in Ireland. These startups also received some very noteworthy clinical/regulatory milestones this year including Clearside Biomedical's completion of Phase III patient enrollment and Accutis' FDA clearance for its Phase II study. We continue to work closely with all Emory licensees to help assure that our technology leads to new products that can benefit patients.

Behind the scenes, are many important activities that often go unnoticed but are critical to our success. For example, our technology scouting team alone met with 260 different faculty to inform, educate and find new invention disclosures. Our dedicated marketing team not only continued to build the office's brand through multiple social media campaigns, but also sent out a record 1,643 non-confidential summaries to prospective corporate partners. On top of that, the Emory Patent Group, our in-house patent firm, received a record number 41 issued patents this year.

We set up many new, innovative collaborations with industry that will help ensure a robust pipeline for the future. A great example of such a collaboration is the new multifaceted master research agreement put in place with a major medical device company and which is targeted at sharing development and IP rights for promising new medical technologies. In addition, we continue to support the development of promising new therapies and medical devices through the execution of new sponsored clinical trial agreements that have resulted in approximately 1,804 active clinical research studies conducted by Emory faculty with approximately 17,070 participants.

I want to thank my staff for their hard work and dedication this past year. All of these records demonstrate your passion and commitment to Emory's success. Well done!

# Product Pipeline

## Therapeutics

Product	Licensee	Preclinical	Phase I	Phase II	Phase III	NDA/BLA	Market
Epivir®	GlaxoSmithKline/Shire	●	●	●	●	●	●
Combivir®	GlaxoSmithKline/Shire	●	●	●	●	●	●
Trizivir®	GlaxoSmithKline/Shire	●	●	●	●	●	●
Epzicom®	GlaxoSmithKline/Shire	●	●	●	●	●	●
Triumeq®	ViiV Healthcare	●	●	●	●	●	●
Dutrebis™	GlaxoSmithKline/Shire	●	●	●	●	●	●
Epivir-HBV®	GlaxoSmithKline/Shire	●	●	●	●	●	●
Emtriva®	Gilead Sciences, Inc.	●	●	●	●	●	●
Truvada®	Gilead Sciences, Inc.	●	●	●	●	●	●
Atripla®	Gilead Sciences, Inc.	●	●	●	●	●	●
Complera®	Gilead Sciences, Inc.	●	●	●	●	●	●
Stribild™	Gilead Sciences, Inc.	●	●	●	●	●	●
Genvoya®	Gilead Sciences, Inc.	●	●	●	●	●	●
Odefsey®	Gilead Sciences, Inc.	●	●	●	●	●	●
Descovy®	Gilead Sciences, Inc.	●	●	●	●	●	●
Tyzeka™	Idenix Pharma.	●	●	●	●	●	●
Obizur®	Baxalta US, Inc.	●	●	●	●	●	●
Obizur®	Baxalta US, Inc.	●	●	●	●	●	●
CLS 1001	Clearside Biomedical, Inc.	●	●	●	●		
elvucitabine	Achillion Pharma.	●	●	●			
DNA/MVA HIV	Vaccine GeoVax, Inc.	●	●	●			
Elate Ocular™	Cambium Medical	●	●	●			
GALE-401	Biovascular	●	●	●			
DNA/MVA	Vaccine GeoVax, Inc.	●	●				
Q-122	QUE Oncology	●	●				

# Product Pipeline

## Diagnostic/Device Products

Requiring 510K Regulatory Processes

Product	Licensee	Prototype	Registration	Trial(s)	510(K)/PMA Application	Market
AnemoCheck™	Sanguina	●	●	●	●	●
Arctic Front®	Biosense Webster	●	●	●	●	●
Arctic Front Advanced®	Biosense Webster	●	●	●	●	●
ClearGlide®	Sorin Group USA	●	●	●	●	●
Emory Cardiac Toolbox™	Syntermed, Inc.	●	●	●	●	●
ExSPECT II™	Syntermed/Philips	●	●	●	●	●
Fragile X Diag. Test *	Quest and others	●	●	●	●	●
IMA Scissors	ICT/Scanlan Int.	●	●	●	●	●
LEGACY Titanium Forceps & Instruments	ICT/Scanlan Int.	●	●	●	●	●
NeoControl®*	Neotonus, Inc.	●	●	●	●	●
NeuroStar						
TMS Therapy®	Neuronetics, LLC	●	●	●	●	●
PetTools™	Syntermed, Inc.	●	●	●	●	●
PVAC®	Biosense Webster	●	●	●	●	●
QA for AlignRT	VisionRT, Ltd.	●	●	●	●	●
QuantEM™	GE Medical Systems	●	●	●	●	●
ReconTools™ (ERTb™)	Syntermed, Inc.	●	●	●	●	●
SyncTools™	Syntermed, Inc.	●	●	●	●	●
ACS System	Thoratec Corporation	●	●	●	●	●
VelocityAI™	Varian Medical Systems	●	●	●	●	●
VelocityGRID™	Varian Medical Systems	●	●	●	●	●
Brijjit	EMRGE	●				
Diabetes Testing	Diasyst	●				
Spectropen	SpectroPath, Inc.	●				

# Product Pipeline

## Diagnostic/Device Products

Requiring IND/IDE/NDA Regulatory Processes

Product	Licensee	Preclinical	Phase I	Phase II	Phase III	NDA	Market
Beta-Cath™	Best Vascular, Inc.	●	●	●	●	●	●
Axumin™	Nihon-Medi-Physics	●	●	●	●	●	●
Imaging Agent	Microbial Medical	●					

## Consumer Products

Product	Licensee	In Development				Market	
ACU-SIBR	Centripital	●	●	●	●	●	●
The Beast™	Avid Capital	●	●	●	●	●	●
Duralast (antimicrob.)*	Duraban International	●	●	●	●	●	●
Handy Eye Chart™	Apple Box	●	●	●	●	●	●
Genetic Testing	EGL Genetics Diagnostics	●	●	●	●	●	●
Goldshield® products*	AuProvis, S.A.	●	●	●	●	●	●
Prokopack	Multiple	●	●	●	●	●	●
RealConsent™	Multiple	●	●	●	●	●	●
SERQET™*	LAAMScience	●	●	●	●	●	●
Sucrets® DEFENSE *	GSH Biomedical Ltd.	●	●	●	●	●	●
VR Solutions	Virtually Better	●	●	●	●	●	●
Alzheimer's Diagnostic	Neurotrack	●	●	●			

\* No longer on the market

Note: A non-exhaustive list of technologies/products that have not received market approval.



## Director's Office

**Todd Sherer, PhD**  
*Associate VP for Research,  
Executive Director*

**Linda Kesselring, MBA**  
*Operations Director*

## Licensing

**J. Cale Lennon, III, PhD, MBA**  
*Director, Licensing*

**Hyeon (Sean) Kim, MBA**  
*Licensing Associate*

**Kim Dunn**  
*Compliance Associate*

**Cliff Michaels, PhD**  
*Assistant Director*

**Kae (Eppley) Gruner, JD**  
*Licensing Associate*

**Raj Guddneppanavar, PhD**  
*Licensing Associate*

**Justin Burns, PhD**  
*Licensing Associate*

**Quentin Thomas, MA**  
*Marketing Manager*

**Vacant**  
*Contract Specialist*

## Faculty and Start-up Services

**Kevin Lei, MBA**  
*Director, Faculty & Start-up Services*

**Patrick Reynolds, PhD**  
*Assistant Director, Faculty &  
Start-up Services*

## Industry Contracting

**Tammie Bain, JD**  
*Assistant Director*

**Shirley Vanier, JD**  
*Lead Analyst*

**Chantrell Lowe**  
*Assoc. Sponsored Research Analyst*

**Daniella Lopez, JD**  
*Sr. Sponsored Research Analyst*

**Mekia Hardy, MBA**  
*Sr. Assoc. Sponsored Research Analyst*

**Vacant**  
*Sr. Assoc. Sponsored Research Analyst*

**Folasade (Sade) Ogunmekan, JD**  
*Sr. Assoc. Sponsored Research Analyst*

## Emory Patent Group

**Laura Fahey Fritts, JD, MBA**  
*Director, License &  
Patent Strategy & Chief Intellectual  
Property Officer*

**Randi Isaacs, JD**  
*Patent Counsel*

**Kristi Rebel**  
*Patent Manager*

**Jim Mason, JD, MS**  
*Patent Counsel*

## Finance

**Lauran Fechte**  
*Senior Financial Analyst*

**Maritta Allison**  
*Senior Accountant*

